A phase I trial of LHC165 single agent and in combination with spartalizumab in patients with advanced solid malignancies

20248 citationsJournal Articlegold Open Access

Authors

Giuseppe Curigliano · University of Milan

M.M. Jimenez · Hospital General Universitario Gregorio Marañón

Tomokazu Shimizu · Tokyo National Hospital

Bhumsuk Keam · Seoul National University Hospital

F. Meric-Bernstam · The University of Texas MD Anderson Cancer Center

A. Rutten · GZA Ziekenhuizen Campus Sint-Augustinus

John A. Glaspy

Abstract

LHC165 demonstrated acceptable safety and tolerability both as SA and in combination with spartalizumab, and evidence of limited antitumor activity was seen in adult patients with relapsed/refractory or metastatic solid tumors.

Topics & Keywords

Cancer Immunotherapy and Biomarkers Immunotherapy and Immune Responses Cancer Research and Treatments

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: ESMO Open

Volume 9, Issue 8, pp. 103643-103643

DOI: 10.1016/j.esmoop.2024.103643

Field-Weighted Citation Impact: 2.26